onvansertib
onvansertib: sourced relationships with 1 company · 5 clinical trials tracked.
onvansertib evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
How could onvansertib → CRDF affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Cardiff Oncology, Inc. (CRDF) Metastatic Colorectal Cancer; Recurrent Chronic Myelomonocyt… | Phase 2 |
Clinical Trial Registry Records (5)
A Phase 1b/2 Trial of Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
Primary endpoint: Overall Response Rate (ORR)
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation
Primary endpoint: Objective Response Rate (ORR)
Phase 1 Study to Determine the Safety and Efficacy of Onvansertib, A Novel, Oral, PLK1 Inhibitor in Patients With Proliferative Chronic Myelomonocytic Leukemia (CMML) and Myelodysplastic Syndrome/MPN Overlap Neoplasms Relapsed/Refractory or Intolerant to Available Therapies
Primary endpoint: Incidence of adverse events
A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma
Primary endpoint: Proportion of all pharmacodynamic feasibility-evaluable participants within a study arm that have a measurable change in post-treatment tumor biology from baseline
A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS Mutation
Primary endpoint: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)
Frequently asked questions
Which companies have sourced relationships with onvansertib?
onvansertib has dated SEC/FDA relationship records for Cardiff Oncology, Inc..
How many clinical trials involve onvansertib?
BioSniper tracks 5 clinical trials involving onvansertib.